RIBOLIFE-B

6938
40.1806.56% ( -2.820 )
Delay Closed: Nov 16, 16:08:11

Overview

RIBOLIFE-B (6938)

Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chine...

Open
41.400
High
43.520
Low
37.500
Prev. Close
43.000
Volume
784.36K
Turnover
30.70M
Avg Price
39.136
Bid/Ask Ratio
-77.78%
Amplitude
14.00%
52wk High
95.800
Volume Ratio
1.95
Turnover Ratio
0.46%
52wk Low
37.500
HK Mkt Cap
6.80B
Market CapHKD
6.80B
P/ETTM
Loss
P/EDynamic
145.49
P/EStatic
--
EPSTTM
-1.15
EPSDynamic
0.276
EPSStatic
--
BVPS
11.76
P/B
3.42
HK Shares
169.27M
Dividend YieldTTM
--
DividendTTM
--
Shares
169.27M
Min lot size
200
Currency
HKD

RIBOLIFE-B Analyst Rating

View more

Forecast & Rating

Oct 16, 2026
Price forecast
HK$100.46150.04%
Forecast & RatingStrong buy
6analysts
  • Strong buy83.33%
  • Buy16.67%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    Suzhou Ribo closed up 3.3% at HK$51.05 after an afternoon rally, reversing an early drop to HK$48.86 for a 7.2% intraday range. The move was driven by the first milestone achievement in the Madrigal collaboration for a MASH siRNA therapy, triggering milestone payments; additionally, the company filed a Phase II clinical trial application with the EMA for its anti-thrombotic siRNA RBD4059 and initiated a Phase III trial in China for the PCSK9 siRNA RBD7022, underscoring pipeline progress. Recent unveiling of the RiboPepSTAR™ platform for extra-hepatic delivery also supported sentiment. However, the stock remains 46.7% below its 52-week high of HK$95.8 and down 37.8% YTD, trading just above the 20-day MA of HK$49.755 but far below the 60-day MA of HK$57.657, with PE at -28.28x and PB at -83.72x reflecting ongoing losses.

News